Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20136490 | 1.00 | POLB (0.31) | POLBAPEX1MEN1KMT2AHPGD | |
| SCHEMBL20136494 | 1.00 | POLB (0.31) | POLBAPEX1MEN1KMT2AHPGD | |
| SCHEMBL18302288 | 0.89 | KDM1A (0.36) | POLBAPEX1HPGDITGB3ITGAV | |
| SCHEMBL18502975 | 0.89 | KDM1A (0.36) | POLBAPEX1HPGDITGB3ITGAV | |
| SCHEMBL18302286 | 0.89 | KDM1A (0.36) | POLBAPEX1HPGDITGB3ITGAV | |
| SCHEMBL2446369 | 0.75 | KMT2A (0.48) | MEN1KMT2AHPGD | |
| SCHEMBL18489289 | 0.75 | GABRA1 (0.31) | — | |
| SCHEMBL18489290 | 0.75 | GABRA1 (0.31) | — | |
| SCHEMBL18502956 | 0.75 | KMT2A (0.48) | MEN1KMT2AHPGD | |
| SCHEMBL15897828 | 0.75 | KDM1A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370370-B2 | Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-08-06 | — | — | US | disclosed |
| US-20180134696-A1 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134696-A1 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370370-B2 | Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | POLB 2813/4885APEX1 4586/4885MEN1 3621/4885 |
| US-20180134696-A1 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | CHRNA7, CHRNA5, CHRNA2 | POLB 2398/4885APEX1 4495/4885MEN1 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.